Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | TDO2 | P48775 | 2/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 7/20 | 0.34 |
| ▸ | KRAS | P01116 | 6/20 | 0.34 |
| ▸ | ACP1 | P24666 | 1/20 | 0.33 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.32 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29426986 | 0.81 | TSHR (0.46) | NOTUMTSHRMAPK1IDO1ACP1 | |
| SCHEMBL134690 | 0.81 | TSHR (0.46) | NOTUMTSHRMAPK1IDO1ACP1 | |
| SCHEMBL3552854 | 0.79 | TSHR (0.36) | TSHRMAPK1PNMTIDO1TDO2 | |
| SCHEMBL3584815 | 0.77 | NOTUM (0.45) | NOTUMPNMTIDO1TDO2ACP1 | |
| SCHEMBL631573 | 0.77 | NOTUM (0.45) | NOTUMPNMTIDO1TDO2ACP1 | |
| SCHEMBL3594814 | 0.77 | NOTUM (0.45) | NOTUMPNMTIDO1TDO2ACP1 | |
| SCHEMBL23149865 | 0.74 | NOTUM (0.39) | NOTUMPNMTIDO1TDO2ACP1 | |
| SCHEMBL7786113 | 0.74 | PNMT (0.44) | NOTUMPNMTIDO1TDO2ACP1 | |
| SCHEMBL6599809 | 0.74 | NOTUM (0.41) | NOTUMPNMTIDO1TDO2ACP1 | |
| SCHEMBL18334820 | 0.73 | KIF11 (0.39) | NOTUMTSHRMAPK1IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193365-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100249024-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7737295-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20070225365-A1 | Cetp Inhibitors | MERCK & CO., INC. (US) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225365-A1 | Cetp Inhibitors | CETP, APOB, NPC1 | NOTUM 173/4885TSHR 3505/4885MAPK1 2498/4885 |
| US-20100249024-A1 | CETP INHIBITORS | CETP, APOB, NPC1 | NOTUM 173/4885TSHR 3505/4885MAPK1 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.